站内搜索 SEARCH
EN
中
凌科致力于
未被满足的临床需求
用创新
为患者的生命带来改变
Lynk is committed to
unmet clinical needs
making a difference
to patients' lives with innovation
关于我们
About Lynk
我们是一家处于临床阶段的创新药研发公司，致力于发现和开发用于治疗癌症以及免疫和炎症性疾病的新药。公司由来自辉瑞（Pfizer)、默克（Merck）和强生（Johnson & Johnson）的资深药物研发专家和高管共同创立。他们在药物研发方面累计总共超过数十年的丰富经验。在更高目标的驱动下，凌科药业旨在成为市场领导者，通过开发创新疗法，应对未被满足的医疗需求。
Lynk Pharmaceuticals is a clinical stage company dedicated to discovering and developing novel medicines to treat oncology, immunology and inflammatory diseases. Lynk Pharmaceuticals was founded by veteran drug hunters from Pfizer, Merck and Johnson & Johnson with collectively more than several decades of rich experiences in drug discovery. Driven by a higher purpose, Lynk aims at growing into a market leader for developing innovative therapies to address unmet medical needs.
左右滑动
看看不一样的万博士
Slide left or slide right,
Check another Dr. Wan
管理团队 Leadership
汪俊博士
共同创始人 & 首席科学官
JUN WANGPh.D.
Co-founder & CSO
MICHAEL VAZQUEZ博士
共同创始人&高级副总裁&化学部负责人
MICHAEL VAZQUEZPh.D.
Co-founder, SVP & Head of Chemistry
陈䶮
共同创始人 & 首席运营官
MR. JAROD CHEN
Co-founder & COO
吴昱博士
首席开发官
HENRY WUPh.D.
CDO
个人背景
BACKGROUND
神户大学博士、德州大学博士后；教授
超过30年学术及工业界新药研发经验 （默克、美迪西生物副总裁) ；
Kobe Unive. (Ph.D.); UT S.W. Medical Center (postdoc)
>25 years @ Merck, Medicilon
个人成就
ACHIEVEMENT
在Nature、PNAS、JBC等著名期刊上发表过多篇文章（通讯作者)、超过40篇国际专利.
Invanz, KU-2285, AK-2123
2015年杰出编委（Biochem. Pharmacol.）
2003年默沙东领导奖
1988年中国医学科学院学术奖
三项期刊编委: Biochem. Pharmacol.、ASSAY & Drug Dev. Tech、 In’t. J. Biol. Sci.
Publications in Nature, PNAS, JBC; >40 US global & regional patents.
Invanz®, KU-2285, AK-2123, Platensimycin & Platencin
Outstanding reviewer for Biochem. Pharmacol. 2015
Leadership Award, Merck, 2003
Distinguished Director, Cancer Institute of CAMS 1989
Editorial Board Members for 3 English Journals
个人背景
BACKGROUND
西北大学博士、RTI博士后
超过30年工业界新药研发经验
辉瑞制药 (总监 & Assc. Research Fellow)
Northwestern Univ. (Ph.D.); RTI (Postdoc)
>30 years @ Pharmacia/Pfizer (Director & Associate Research Fellow)
个人成就
ACHIEVEMENT
超过20篇论文发表、超过470个全球专利
PF-04965842 (三期临床)、PF-06763809 (Phase Ib)、Agenerase®、Lexiva®、Prezista® & Xalkori®
北伊利诺伊大学杰出校友 (2016)
>20 Journal publications; >470 global & regional patents.
Agenerase®, Lexiva®, Prezista® & Xalkori®, PF-04965842 (Phase III), PF-06763809 (Phase Ib)
Distinguished Alumni (2016), Northern Illinois University
Frequently invited speakers at conferences & universities
个人背景
BACKGROUND
杜克大学富卡商学院量化管理硕士（医疗方向）
中国药科大学博士肄业、首尔国立大学访问学者
超过11年医药工业界营销管理及投融资经验（国药、康恩贝、东诚药业、长江资本）
Duke Univ., Fuqua School of Business (MSQM: HA 2020-2022)
China Pharmaceuticals University(Ph.D. candidate) Seoul University (Visiting Scholar)
>11 years @ Changjiang Capital, Sinopharm, Conba
Broad experience in investment and operation
个人成就
ACHIEVEMENT
曾负责多家上市公司产品营销管理
燧池医药创始人
参与过多个生物医药项目投资及投后管理
浙江药学会药事管理专业委员会委员
基金从业资格证
Responsible for product marketing management of several listed companies
Participated in biotech investment & post investment management
Certified mutual fund manager.
Member of Pharmaceutical Management Committee, Zhejiang
Pharmaceutical Association
个人背景
BACKGROUND
美国新泽西州立罗格斯大学博士
超过20年工业界研发经验（罗氏、森林实验室、方恩、希麦迪等）
美国Innotics创始人及首席统计师
前方恩(Fountain)公司首席运营官、首席执行官
希麦迪(CR Medicon)公司创始人、前首席执行官及董事长
Rutgers Univ (Ph.D.)
> 23 years @ Roche, Innotics (Founder), Kendle, Fountain (CEO), CR Medicon (Founder, CEO & Chairman of Board).
个人成就
ACHIEVEMENT
参与和领导了不同的治疗领域进行了200多项临床试验。
领导了20项不同治疗领域的NDA/BLA提交
Led/Participated in over 200 clinical trials in different therapeutic areas. Managed and interacted with multi-disciplinary team members including data managers, statisticians, programmers, medical writers, and clinicians.
Led over 20 NDA/BLA submissions in different therapeutic areas, overall submission strategy design and cross functional team discussion.
顾问委员会 Advisors
Dr. Michael Kahn
顾问委员会主席
美国希望之城国家医疗中心贝克曼研究中心生物学系 主任
Dr. Michael Kahn
Chairman of Advisory Board
Chairman, Beckman research Institute, City of Hope, USA
Dr. Guido Marcucci
Gehr 家族白血病研究中心：主任
美国希望之城国家医疗中心血液恶性肿瘤转化科学系 主任
Dr. Guido Marcucci
Chairman, Beckman research Institute, City of Hope, USA
Chairman, Department of Hematologic Malignancies Translational Science, City of Hope, USA
谭蔚泓院士
中科院基础医学与肿瘤研究所所长
浙江肿瘤医院院长
PROF.WEIHONG TAN
Director, Institute of Cancer & Basic Medicine
Academician, the Chinese Academy of Sciences
寿亚萍博士
美国Trillium Therapeutics首席医学官
DR.YAPING SHOU
CMO, Trillium Therapeutics, Cambridge, MA
公司荣誉 Awards
2018
第七届中国创新创业大赛生物医药行业（初创组）一等奖
2018
第七届中国创新创业大赛（初创组）优秀企业
2019
2019 沙利文中国新经济卓越科创奖
2020
杭州市钱塘新区高层次人才企业最具发展动力奖
2021
杭州市准独角兽企业
 
2018
第七届中国创新创业大赛生物医药行业（初创组）一等奖
2018
第七届中国创新创业大赛（初创组）优秀企业
2019
2019 沙利文中国新经济卓越科创奖
2020
杭州市钱塘新区高层次人才企业最具发展动力奖
2021
杭州市准独角兽企业
（估值达1亿美金以上企业）
2018
The first prize of biomedical industry (start-up group) in the 7th China Innovation and Entrepreneurship Competition
2018
Excellent enterprise of the 7th China Innovation and Entrepreneurship Competition (start-up group)
2019
2019 Frost & Sullivan China New Economy Award-Excellence in Innovation

2020
Hangzhou Qiantang New Area high-level talent enterprise most driving force Award

2021
Hangzhou quasi Unicorn enterprise


2018
The first prize of biomedical industry (start-up group) in the 7th China Innovation and Entrepreneurship Competition
2018
Excellent enterprise of the 7th China Innovation and Entrepreneurship Competition (start-up group)
2019
2019 Frost & Sullivan China New Economy Award-Excellence in Innovation

2020
Hangzhou Qiantang New Area high-level talent enterprise most driving force Award

2021
Hangzhou quasi Unicorn enterprise


联系我们 Contact Us
美国，波士顿
Boston, USA
 
1337 Massachusetts Ave,
Suite 168, Arlington,
MA 02476
浙江省，杭州市，钱塘新区
Qiantang New District, Hangzhou, China
浙江省杭州市
钱塘新区福城路291号
5号楼402室
291 Fucheng Road,
Bldg 5-402, Qiantang,
Hangzhou, Zhejiang, China
上海市，静安区
Jing’an District, Shanghai, China
上海市静安区
南京西路1717号
会德丰国际广场26楼
26/F, Wheelock Square,
1717 Nanjing West Road,
Jing'an District, Shanghai
如需了解更多信息或其他查询
For more information